西地那非联合吡非尼酮治疗晚期特发性肺纤维化伴肺动脉高压风险的2b期试验
这项多中心、国际、双盲、随机、安慰剂对照的2b期研究纳入了177例晚期IPF且存在第3组肺动脉高压风险的患者,随机接受西地那非或安慰剂联合吡非尼酮治疗52周。安全性方面,严重治疗中出现的不良事件发生率相似(61% vs 62%)。
要点
- 西地那非联合吡非尼酮未改善晚期IPF伴肺动脉高压风险患者的疾病进展。
- 两组严重不良事件及致死性不良事件发生率相似,未发现新安全信号。
- 研究提示西地那非不适用于该整体人群,特定亚组获益仍需进一步研究。
核心结论
- 在晚期IPF且有第3组肺动脉高压风险的患者中,西地那非联合吡非尼酮与安慰剂联合吡非尼酮相比,52周内未提供治疗获益。
- 未发现西地那非或安慰剂联合吡非尼酮的新安全信号。
- 尽管整体人群无获益,特定亚组是否获益仍需进一步研究。
研究设计与样本
- 多中心、国际、双盲、随机、安慰剂对照的2b期研究,在56个大学诊所、研究医院和三级中心开展。
- 纳入年龄40-80岁、晚期IPF(筛查时DLCO≤40%预计值)且有第3组肺动脉高压风险的患者。
- 177例患者随机1:1接受口服西地那非20mg每日三次或安慰剂,均联合口服吡非尼酮801mg每日三次,治疗52周。
- 复合主要终点为52周疾病进展(6分钟步行距离相关下降、呼吸相关住院或全因死亡),在意向治疗人群中评估。
主要发现
- 严重治疗中出现的不良事件在西地那非组54例(61%)和安慰剂组55例(62%)中报告。
- 导致死亡的治疗中出现的不良事件在西地那非组22例(25%)和安慰剂组26例(29%)中发生。
关键数值与推荐
- 晚期IPF定义:筛查时一氧化碳弥散量≤40%预计值。
- 第3组肺动脉高压风险定义:既往右心导管检查示平均肺动脉压≥20 mmHg且肺动脉楔压≤15 mmHg,或超声心动图提示第3组肺动脉高压中/高概率(依据2015年ESC/ERS指南)。
- 主要终点疾病进展定义:6分钟步行距离相关下降、呼吸相关住院或全因死亡。
临床怎么用
- 对于晚期IPF且有肺动脉高压风险的患者,不推荐常规加用西地那非联合吡非尼酮治疗。
- 临床决策应基于整体证据,西地那非在该人群中的使用需谨慎评估。
局限性
- 研究仅纳入晚期IPF且有肺动脉高压风险的患者,结果不能外推至其他IPF人群。
- 11个月安全性随访仍在进行中,长期安全性数据尚未获得。
- 特定亚组是否可能获益尚未确定,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The benefit of sildenafil in patients with advanced idiopathic pulmonary fibrosis (IPF) at risk of poor outcomes from pulmonary hypertension, whether already present or likely to develop, is uncertain. We aimed to assess the efficacy and safety of sildenafil added to pirfenidone versus placebo added to pirfenidone for 52 weeks in patients with advanced IPF and at risk of group 3 pulmonary hypertension. METHODS: We did a multicentre, international, double-blind, randomised, placebo-controlled, phase 2b study at 56 university clinics, research hospitals, and tertiary sites in Canada, Europe (Belgium, Czech Republic, Germany, Greece, Hungary, Italy, the Netherlands, Spain, and Turkey), Israel, and Africa (Egypt and South Africa). Eligible patients (aged 40-80 years) had advanced IPF (carbon monoxide diffusing capacity ≤40% predicted at screening), and were at risk of group 3 pulmonary hypertension (mean pulmonary artery pressure of ≥20 mm Hg with pulmonary artery wedge pressure of ≤15 mm Hg on previous right-heart catheterisation, or intermediate or high probability of group 3 pulmonary hypertension on echocardiography as defined by the 2015 European Society of Cardiology and European Respiratory Society guidelines). Patients were randomly assigned 1:1 to oral sildenafil tablets (20 mg three times daily) or placebo, both in addition to oral pirfenidone capsules (801 mg three times daily), using a validated interactive voice-based or web-based response system with permuted block randomisation, stratified by previous right-heart catheterisation (yes or no) and forced expiratory volume in 1 s to forced vital capacity ratio (<0·8 or ≥0·8). The composite primary endpoint was disease progression, defined as either a relevant decline in 6-min walk distance, respiratory-related admission to hospital, or all-cause mortality, after 52 weeks and was assessed in the intention-to-treat population; safety was assessed in all patients who received at least one dose of the study drug. This trial is registered with ClinicalTrials.gov, NCT02951429, and is no longer recruiting. The 11-month safety follow-up is ongoing. FINDINGS: Between Jan 13, 2017, and Aug 30, 2018, 247 patients were screened for eligibility, 177 of whom were randomly assigned to a treatment group (n=88 sildenafil; n=89 placebo) and were assessed for the primary outcome. There was no difference in the proportion of patients with disease progression over 52 weeks between the sildenafil (64 [73%] of 88 patients) and placebo groups (62 [70%] of 89 patients; between-group difference 3·06% [95% CI -11·30 to 17·97]; p=0·65). Serious treatment-emergent adverse events were reported in 54 (61%) patients in the sildenafil group and 55 (62%) patients in the placebo group. Treatment-emergent adverse events leading to mortality occurred in 22 (25%) patients in the sildenafil group and 26 (29%) in the placebo group. INTERPRETATION: Addition of sildenafil to pirfenidone did not provide a treatment benefit versus pirfenidone plus placebo up to 52 weeks in patients with advanced IPF and risk of pulmonary hypertension. No new safety signals were identified with either treatment. Although the absence of a beneficial treatment effect suggests that sildenafil is not an appropriate treatment in the overall population, further research is required to establish if specific subgroups of patients with IPF might benefit from sildenafil. FUNDING: F Hoffmann-La Roche.
引用
- Behr J, Nathan SD, Wuyts WA, et al. Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2020. PMID: 32822614. doi:10.1016/S2213-2600(20)30356-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。